It blocks the interaction between Smad2/3-TGF β RI proteins and inhibits Smad2/3 phosphorylation, thereby inhibiting RAS the TGF - β/Smad pathway, ultimately leading to the treatment of chronic kidney disease. This evidence concerns the gene SMAD2 and chronic kidney disease.